Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

Biocraft, Quantum Pharmics, and Colmed Labs received ANDA approvals for 10 mg metoclopramide tabs on July 29. The generics to Robins' Reglan were approved for the "relief of symptoms associated with acute and recurrent diabetic gastric stasis." Reglan carries additional indications including uses for gastroesophageal reflux and relief of nausea and vomiting due to cancer chemotherapy. Biocraft is pricing its version between 55% and 57% below Reglan's published prices; Quantum's branded generic price is about 42% below Robins'. Biocraft's price to whslrs. is $10.50 for 100s and $47 for 500s. Quantum's suggested whsle. price for its Clopra brand is $13.86 for 100s and $65.74 for 500s. The Redbook lists Reglan's average whsle. price at $23.55 for 100s and $111.80 for 500s. Robins will be facing generic competition to its largest selling Rx product. In its 1984 annual report, the company reported that Reglan volume increased 49% to approximately $60 mil. The tablet form enjoyed only four years of marketing exclusivity. FDA approved the tablet in 1981; the I.V. "dosage was approved in 1979. Metoclopramide is Biocraft's second major post-1962 ANDA approval in the past several months. In February, the firm received the first ANDA for dysopyramide (Searle's Norpace). Colorado-based Colmed received FDA approval for one post-1962 product in the past year, chlorpropamide. The generic to Pfizer's Diabinese was approved in August 1984. Metoclopramide and propranolol were approved during the same week (see previous story). Propranolol is the seventh drug among the Top 20 retail Rx products to lose its marketing exclusivity in the past year. The other products now facing multi-source competition, excluding oral contraceptives, are Aldomet, Dyazide, Diabinese, Indocin, Darvocet-N and Motrin,

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts